img

Global Venous Thromboembolism Drug Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Venous Thromboembolism Drug Market Research Report 2024

Venous Thromboembolism includes both deep vein thrombosis (DVT) and pulmonary embolism (PE).
According to Mr Accuracy reports new survey, global Venous Thromboembolism Drug market is projected to reach US$ 3272.5 million in 2029, increasing from US$ 2254 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Venous Thromboembolism Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Venous Thromboembolism Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Bayer
BMS
Boehringer Ingelheim
Daiichi Sankyo
J&J
Sanofi
Altor Bioscience
Armetheon
Aspen Pharma
BioInvent
eXIthera Pharmaceuticals
Gamma Therapeutics
Segment by Type
Heparin
Apixaban
Dabigatran
Rivaroxaban
Edaxaban
Warfarin

Segment by Application


Hospital
Clinic

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Venous Thromboembolism Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Venous Thromboembolism Drug Market Overview
1.1 Product Overview and Scope of Venous Thromboembolism Drug
1.2 Venous Thromboembolism Drug Segment by Type
1.2.1 Global Venous Thromboembolism Drug Market Value Comparison by Type (2024-2034)
1.2.2 Heparin
1.2.3 Apixaban
1.2.4 Dabigatran
1.2.5 Rivaroxaban
1.2.6 Edaxaban
1.2.7 Warfarin
1.3 Venous Thromboembolism Drug Segment by Application
1.3.1 Global Venous Thromboembolism Drug Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Venous Thromboembolism Drug Market Size Estimates and Forecasts
1.4.1 Global Venous Thromboembolism Drug Revenue 2018-2029
1.4.2 Global Venous Thromboembolism Drug Sales 2018-2029
1.4.3 Global Venous Thromboembolism Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Venous Thromboembolism Drug Market Competition by Manufacturers
2.1 Global Venous Thromboembolism Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Venous Thromboembolism Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Venous Thromboembolism Drug Average Price by Manufacturers (2018-2024)
2.4 Global Venous Thromboembolism Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Venous Thromboembolism Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Venous Thromboembolism Drug, Product Type & Application
2.7 Venous Thromboembolism Drug Market Competitive Situation and Trends
2.7.1 Venous Thromboembolism Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Venous Thromboembolism Drug Players Market Share by Revenue
2.7.3 Global Venous Thromboembolism Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Venous Thromboembolism Drug Retrospective Market Scenario by Region
3.1 Global Venous Thromboembolism Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Venous Thromboembolism Drug Global Venous Thromboembolism Drug Sales by Region: 2018-2029
3.2.1 Global Venous Thromboembolism Drug Sales by Region: 2018-2024
3.2.2 Global Venous Thromboembolism Drug Sales by Region: 2024-2029
3.3 Global Venous Thromboembolism Drug Global Venous Thromboembolism Drug Revenue by Region: 2018-2029
3.3.1 Global Venous Thromboembolism Drug Revenue by Region: 2018-2024
3.3.2 Global Venous Thromboembolism Drug Revenue by Region: 2024-2029
3.4 North America Venous Thromboembolism Drug Market Facts & Figures by Country
3.4.1 North America Venous Thromboembolism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Venous Thromboembolism Drug Sales by Country (2018-2029)
3.4.3 North America Venous Thromboembolism Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Venous Thromboembolism Drug Market Facts & Figures by Country
3.5.1 Europe Venous Thromboembolism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Venous Thromboembolism Drug Sales by Country (2018-2029)
3.5.3 Europe Venous Thromboembolism Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Venous Thromboembolism Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Venous Thromboembolism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Venous Thromboembolism Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Venous Thromboembolism Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Venous Thromboembolism Drug Market Facts & Figures by Country
3.7.1 Latin America Venous Thromboembolism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Venous Thromboembolism Drug Sales by Country (2018-2029)
3.7.3 Latin America Venous Thromboembolism Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Venous Thromboembolism Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Venous Thromboembolism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Venous Thromboembolism Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Venous Thromboembolism Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Venous Thromboembolism Drug Sales by Type (2018-2029)
4.1.1 Global Venous Thromboembolism Drug Sales by Type (2018-2024)
4.1.2 Global Venous Thromboembolism Drug Sales by Type (2024-2029)
4.1.3 Global Venous Thromboembolism Drug Sales Market Share by Type (2018-2029)
4.2 Global Venous Thromboembolism Drug Revenue by Type (2018-2029)
4.2.1 Global Venous Thromboembolism Drug Revenue by Type (2018-2024)
4.2.2 Global Venous Thromboembolism Drug Revenue by Type (2024-2029)
4.2.3 Global Venous Thromboembolism Drug Revenue Market Share by Type (2018-2029)
4.3 Global Venous Thromboembolism Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Venous Thromboembolism Drug Sales by Application (2018-2029)
5.1.1 Global Venous Thromboembolism Drug Sales by Application (2018-2024)
5.1.2 Global Venous Thromboembolism Drug Sales by Application (2024-2029)
5.1.3 Global Venous Thromboembolism Drug Sales Market Share by Application (2018-2029)
5.2 Global Venous Thromboembolism Drug Revenue by Application (2018-2029)
5.2.1 Global Venous Thromboembolism Drug Revenue by Application (2018-2024)
5.2.2 Global Venous Thromboembolism Drug Revenue by Application (2024-2029)
5.2.3 Global Venous Thromboembolism Drug Revenue Market Share by Application (2018-2029)
5.3 Global Venous Thromboembolism Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Bayer Venous Thromboembolism Drug Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 BMS
6.2.1 BMS Corporation Information
6.2.2 BMS Description and Business Overview
6.2.3 BMS Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 BMS Venous Thromboembolism Drug Product Portfolio
6.2.5 BMS Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Boehringer Ingelheim Venous Thromboembolism Drug Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Daiichi Sankyo
6.4.1 Daiichi Sankyo Corporation Information
6.4.2 Daiichi Sankyo Description and Business Overview
6.4.3 Daiichi Sankyo Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Daiichi Sankyo Venous Thromboembolism Drug Product Portfolio
6.4.5 Daiichi Sankyo Recent Developments/Updates
6.5 J&J
6.5.1 J&J Corporation Information
6.5.2 J&J Description and Business Overview
6.5.3 J&J Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 J&J Venous Thromboembolism Drug Product Portfolio
6.5.5 J&J Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Sanofi Venous Thromboembolism Drug Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
6.7 Altor Bioscience
6.6.1 Altor Bioscience Corporation Information
6.6.2 Altor Bioscience Description and Business Overview
6.6.3 Altor Bioscience Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Altor Bioscience Venous Thromboembolism Drug Product Portfolio
6.7.5 Altor Bioscience Recent Developments/Updates
6.8 Armetheon
6.8.1 Armetheon Corporation Information
6.8.2 Armetheon Description and Business Overview
6.8.3 Armetheon Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Armetheon Venous Thromboembolism Drug Product Portfolio
6.8.5 Armetheon Recent Developments/Updates
6.9 Aspen Pharma
6.9.1 Aspen Pharma Corporation Information
6.9.2 Aspen Pharma Description and Business Overview
6.9.3 Aspen Pharma Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Aspen Pharma Venous Thromboembolism Drug Product Portfolio
6.9.5 Aspen Pharma Recent Developments/Updates
6.10 BioInvent
6.10.1 BioInvent Corporation Information
6.10.2 BioInvent Description and Business Overview
6.10.3 BioInvent Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 BioInvent Venous Thromboembolism Drug Product Portfolio
6.10.5 BioInvent Recent Developments/Updates
6.11 eXIthera Pharmaceuticals
6.11.1 eXIthera Pharmaceuticals Corporation Information
6.11.2 eXIthera Pharmaceuticals Venous Thromboembolism Drug Description and Business Overview
6.11.3 eXIthera Pharmaceuticals Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.11.4 eXIthera Pharmaceuticals Venous Thromboembolism Drug Product Portfolio
6.11.5 eXIthera Pharmaceuticals Recent Developments/Updates
6.12 Gamma Therapeutics
6.12.1 Gamma Therapeutics Corporation Information
6.12.2 Gamma Therapeutics Venous Thromboembolism Drug Description and Business Overview
6.12.3 Gamma Therapeutics Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Gamma Therapeutics Venous Thromboembolism Drug Product Portfolio
6.12.5 Gamma Therapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Venous Thromboembolism Drug Industry Chain Analysis
7.2 Venous Thromboembolism Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Venous Thromboembolism Drug Production Mode & Process
7.4 Venous Thromboembolism Drug Sales and Marketing
7.4.1 Venous Thromboembolism Drug Sales Channels
7.4.2 Venous Thromboembolism Drug Distributors
7.5 Venous Thromboembolism Drug Customers
8 Venous Thromboembolism Drug Market Dynamics
8.1 Venous Thromboembolism Drug Industry Trends
8.2 Venous Thromboembolism Drug Market Drivers
8.3 Venous Thromboembolism Drug Market Challenges
8.4 Venous Thromboembolism Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Venous Thromboembolism Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Venous Thromboembolism Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Venous Thromboembolism Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Venous Thromboembolism Drug Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Venous Thromboembolism Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Venous Thromboembolism Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Venous Thromboembolism Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Venous Thromboembolism Drug Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Venous Thromboembolism Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Venous Thromboembolism Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Venous Thromboembolism Drug, Product Type & Application
Table 12. Global Key Manufacturers of Venous Thromboembolism Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Venous Thromboembolism Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Venous Thromboembolism Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Venous Thromboembolism Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Venous Thromboembolism Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Venous Thromboembolism Drug Sales Market Share by Region (2018-2024)
Table 19. Global Venous Thromboembolism Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Venous Thromboembolism Drug Sales Market Share by Region (2024-2029)
Table 21. Global Venous Thromboembolism Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Venous Thromboembolism Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Venous Thromboembolism Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Venous Thromboembolism Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Venous Thromboembolism Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Venous Thromboembolism Drug Sales by Country (2018-2024) & (K Units)
Table 27. North America Venous Thromboembolism Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Venous Thromboembolism Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Venous Thromboembolism Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Venous Thromboembolism Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Venous Thromboembolism Drug Sales by Country (2018-2024) & (K Units)
Table 32. Europe Venous Thromboembolism Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Venous Thromboembolism Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Venous Thromboembolism Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Venous Thromboembolism Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Venous Thromboembolism Drug Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Venous Thromboembolism Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Venous Thromboembolism Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Venous Thromboembolism Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Venous Thromboembolism Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Venous Thromboembolism Drug Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Venous Thromboembolism Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Venous Thromboembolism Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Venous Thromboembolism Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Venous Thromboembolism Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Venous Thromboembolism Drug Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Venous Thromboembolism Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Venous Thromboembolism Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Venous Thromboembolism Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Venous Thromboembolism Drug Sales (K Units) by Type (2018-2024)
Table 51. Global Venous Thromboembolism Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Venous Thromboembolism Drug Sales Market Share by Type (2018-2024)
Table 53. Global Venous Thromboembolism Drug Sales Market Share by Type (2024-2029)
Table 54. Global Venous Thromboembolism Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Venous Thromboembolism Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Venous Thromboembolism Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Venous Thromboembolism Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Venous Thromboembolism Drug Price (US$/Unit) by Type (2018-2024)
Table 59. Global Venous Thromboembolism Drug Price (US$/Unit) by Type (2024-2029)
Table 60. Global Venous Thromboembolism Drug Sales (K Units) by Application (2018-2024)
Table 61. Global Venous Thromboembolism Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Venous Thromboembolism Drug Sales Market Share by Application (2018-2024)
Table 63. Global Venous Thromboembolism Drug Sales Market Share by Application (2024-2029)
Table 64. Global Venous Thromboembolism Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Venous Thromboembolism Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Venous Thromboembolism Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Venous Thromboembolism Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Venous Thromboembolism Drug Price (US$/Unit) by Application (2018-2024)
Table 69. Global Venous Thromboembolism Drug Price (US$/Unit) by Application (2024-2029)
Table 70. Bayer Corporation Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Bayer Venous Thromboembolism Drug Product
Table 74. Bayer Recent Developments/Updates
Table 75. BMS Corporation Information
Table 76. BMS Description and Business Overview
Table 77. BMS Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. BMS Venous Thromboembolism Drug Product
Table 79. BMS Recent Developments/Updates
Table 80. Boehringer Ingelheim Corporation Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Boehringer Ingelheim Venous Thromboembolism Drug Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Daiichi Sankyo Corporation Information
Table 86. Daiichi Sankyo Description and Business Overview
Table 87. Daiichi Sankyo Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Daiichi Sankyo Venous Thromboembolism Drug Product
Table 89. Daiichi Sankyo Recent Developments/Updates
Table 90. J&J Corporation Information
Table 91. J&J Description and Business Overview
Table 92. J&J Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. J&J Venous Thromboembolism Drug Product
Table 94. J&J Recent Developments/Updates
Table 95. Sanofi Corporation Information
Table 96. Sanofi Description and Business Overview
Table 97. Sanofi Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Sanofi Venous Thromboembolism Drug Product
Table 99. Sanofi Recent Developments/Updates
Table 100. Altor Bioscience Corporation Information
Table 101. Altor Bioscience Description and Business Overview
Table 102. Altor Bioscience Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Altor Bioscience Venous Thromboembolism Drug Product
Table 104. Altor Bioscience Recent Developments/Updates
Table 105. Armetheon Corporation Information
Table 106. Armetheon Description and Business Overview
Table 107. Armetheon Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Armetheon Venous Thromboembolism Drug Product
Table 109. Armetheon Recent Developments/Updates
Table 110. Aspen Pharma Corporation Information
Table 111. Aspen Pharma Description and Business Overview
Table 112. Aspen Pharma Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Aspen Pharma Venous Thromboembolism Drug Product
Table 114. Aspen Pharma Recent Developments/Updates
Table 115. BioInvent Corporation Information
Table 116. BioInvent Description and Business Overview
Table 117. BioInvent Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. BioInvent Venous Thromboembolism Drug Product
Table 119. BioInvent Recent Developments/Updates
Table 120. eXIthera Pharmaceuticals Corporation Information
Table 121. eXIthera Pharmaceuticals Description and Business Overview
Table 122. eXIthera Pharmaceuticals Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. eXIthera Pharmaceuticals Venous Thromboembolism Drug Product
Table 124. eXIthera Pharmaceuticals Recent Developments/Updates
Table 125. Gamma Therapeutics Corporation Information
Table 126. Gamma Therapeutics Description and Business Overview
Table 127. Gamma Therapeutics Venous Thromboembolism Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Gamma Therapeutics Venous Thromboembolism Drug Product
Table 129. Gamma Therapeutics Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Venous Thromboembolism Drug Distributors List
Table 133. Venous Thromboembolism Drug Customers List
Table 134. Venous Thromboembolism Drug Market Trends
Table 135. Venous Thromboembolism Drug Market Drivers
Table 136. Venous Thromboembolism Drug Market Challenges
Table 137. Venous Thromboembolism Drug Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Venous Thromboembolism Drug
Figure 2. Global Venous Thromboembolism Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Venous Thromboembolism Drug Market Share by Type in 2022 & 2029
Figure 4. Heparin Product Picture
Figure 5. Apixaban Product Picture
Figure 6. Dabigatran Product Picture
Figure 7. Rivaroxaban Product Picture
Figure 8. Edaxaban Product Picture
Figure 9. Warfarin Product Picture
Figure 10. Global Venous Thromboembolism Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 11. Global Venous Thromboembolism Drug Market Share by Application in 2022 & 2029
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Global Venous Thromboembolism Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Venous Thromboembolism Drug Market Size (2018-2029) & (US$ Million)
Figure 16. Global Venous Thromboembolism Drug Sales (2018-2029) & (K Units)
Figure 17. Global Venous Thromboembolism Drug Average Price (US$/Unit) & (2018-2029)
Figure 18. Venous Thromboembolism Drug Report Years Considered
Figure 19. Venous Thromboembolism Drug Sales Share by Manufacturers in 2022
Figure 20. Global Venous Thromboembolism Drug Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest Venous Thromboembolism Drug Players: Market Share by Revenue in 2022
Figure 22. Venous Thromboembolism Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global Venous Thromboembolism Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 24. North America Venous Thromboembolism Drug Sales Market Share by Country (2018-2029)
Figure 25. North America Venous Thromboembolism Drug Revenue Market Share by Country (2018-2029)
Figure 26. United States Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe Venous Thromboembolism Drug Sales Market Share by Country (2018-2029)
Figure 29. Europe Venous Thromboembolism Drug Revenue Market Share by Country (2018-2029)
Figure 30. Germany Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. France Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. U.K. Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Italy Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Russia Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Asia Pacific Venous Thromboembolism Drug Sales Market Share by Region (2018-2029)
Figure 36. Asia Pacific Venous Thromboembolism Drug Revenue Market Share by Region (2018-2029)
Figure 37. China Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Japan Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. South Korea Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. India Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Australia Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. China Taiwan Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Indonesia Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Thailand Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Malaysia Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Latin America Venous Thromboembolism Drug Sales Market Share by Country (2018-2029)
Figure 47. Latin America Venous Thromboembolism Drug Revenue Market Share by Country (2018-2029)
Figure 48. Mexico Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Brazil Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Argentina Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Middle East & Africa Venous Thromboembolism Drug Sales Market Share by Country (2018-2029)
Figure 52. Middle East & Africa Venous Thromboembolism Drug Revenue Market Share by Country (2018-2029)
Figure 53. Turkey Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. UAE Venous Thromboembolism Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Global Sales Market Share of Venous Thromboembolism Drug by Type (2018-2029)
Figure 57. Global Revenue Market Share of Venous Thromboembolism Drug by Type (2018-2029)
Figure 58. Global Venous Thromboembolism Drug Price (US$/Unit) by Type (2018-2029)
Figure 59. Global Sales Market Share of Venous Thromboembolism Drug by Application (2018-2029)
Figure 60. Global Revenue Market Share of Venous Thromboembolism Drug by Application (2018-2029)
Figure 61. Global Venous Thromboembolism Drug Price (US$/Unit) by Application (2018-2029)
Figure 62. Venous Thromboembolism Drug Value Chain
Figure 63. Venous Thromboembolism Drug Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries